PROF. DR. HASNIZA BINTI ZAMAN HURI
Department of Clinical Pharmacy and Pharmacy Practice
Faculty of Pharmacy
hasnizazhum.edu.myView CV | |
Publons | |
Scopus Link | |
Biography | |
Professor Dr Hasniza Zaman Huri is an accomplished academic pharmacist and the founding Dean of the Faculty of Pharmacy at Universiti Malaya. Under her leadership, the faculty has achieved numerous accolades, including being a founding member of the Global Alliance for the Development of Pharmaceutical Science (GADPS), an alliance to spearhead the excellent teaching & learning and research of pharmacy/pharmaceutical sciences school around the globe, the top KPI achiever for academic centre in 2023, top faculty for graduate employability and for the first time, top 100 (#72) for Pharmacy subject ranking in the QS World University Rankings 2024. Professor Dr Hasniza was also appointed as the General Assembly Representative for GADPS. As a leading clinical scientist in clinical pharmacy, precision medicine and targeted therapy, she was honoured with the World Class Professor Programme by the Indonesian Government in 2022, among 78 professors globally. Professor Dr Hasniza's research expertise focuses on targeted therapy, drug utilisation and precision medicine, especially in metabolic diseases. She has been invited by various countries such as the United Kingdom, Uzbekistan, Turkey, China, India, Taiwan, and Indonesia as a Keynote or Plenary Speaker at conferences. She has published over 100 publications indexed in the Web of Science (WoS). Professor Dr Hasniza is also an expert in the clinical trial industry and is recognized for her exemplary leadership. She was the Manager and later Director of the Clinical Investigation Centre (CIC) at the University Malaya Medical Centre (UMMC). During her tenure, CIC UMMC gained a world-class reputation, winning multiple distinctions, including being the first Strategic Alliance Site for Parexel Inc. in Malaysia, Pfizer’s INSPIRE (Investigator Networks, Site Partnerships and Infrastructure for Research Excellence) Site in Malaysia, Best Clinical Trial Service Provider in Asia, Top-10 IQVIA Prime Sites in the world and many more. She was awarded Best Academic Administrator for Non-Academic Centre in 2015 by Universiti Malaya and recently, in 2024, was awarded the MPS Outstanding Leadership Award by the Malaysian Pharmacists Society (MPS), an excellence award due to her outstanding performance and exceptional achievement in pharmacy practice in Malaysia. She is also the Honorary Visiting Consultant at CIC and a member of the Drug Control Authority (DCA) Ministry of Health, Malaysia.
|
Publication
Finance
Project Title | Progress | Status |
---|---|---|
Targeting Lipogenic Pathway In T2dm Patients With Cardiovascular Disease: Unravelling The Cardio-protective Mechanism Of Sglt2-inhibitor On Epicardial Fat Thickness Via Multi-omics Approach |
|
new |
"health Intervention Programme And Public Perception In The Management Of Non-communicable Diseases (ncds) In Community Pharmacy In Malaysia " |
|
on going |
Pharmacokinetics-pharmacometabolomics Profiling Of Registered Andographis Paniculata |
|
end |
This information is generated from Research Grant Management System |
Association of the Reduced Function Met420del Polymorphism of SLC22A1 with Metformin-Induced Gastrointestinal Intolerance in Ethiopian Patients with Type 2 Diabetes Mellitus
The impact of perceived vaginal and urinary symptoms and treatment burden in predicting sexual functioning among perimenopausal and postmenopausal women
Ethnic disparities and its association between epicardial adipose tissue thickness and cardiometabolic parameters
Personalised learning in higher education for health sciences: a scoping review protocol
Utilisation of Variable Rate Intravenous Insulin Infusion
Biolubricant Base Oil Synthesis and Its Application: Pharmaceutical and Industrial Applications Based on Enviromental Friendly
Hydrolysis, Separation and Purification of Fatty Acids for Bioproducts
Training Manual for Pharmacists for Management of Obesity and Overweight.
Dyslipidemia and Type 2 Diabetes Mellitus: Implications and Role of Antiplatelet Agents in Primary Prevention of Cardiovascular Disease
Dyslipidemia and type 2 diabetes mellitus: Implications and role of antiplatelet agents in primary prevention of cardiovascular diseases.